MTInov

The MTInov platform offers a full range of services, from support and regulatory advice to production and quality control.

Thanks to our experience in various research and clinical research projects, we are able to handle scale-up and industrialisation for different cell types: adherent cells (UC-MSC, BM-PSC) or in suspension (anti-viral T lymphocytes, CAR-T cells, NK cells, iNKT or MDSC). This enables us to offer you solutions tailored to the cell models you are working on. Adapting a 2D process to a 3D process, particularly in a bioreactor, right through to transfer to clinical grade conditions. The MTInov platform’s areas of expertise therefore cover both the clinical-grade production of cell- or tissue-based drugs and the development of suspension or adherent culture processes in bioreactors.

This ensures continuity between pre-clinical development, scale-up and transfer to clinical grade in order to optimise production performance.

MTInov’s long-term viability depends on a number of factors, the most important of which are: the quality of the service provided, the ability to adapt premises capacity and production capacity in terms of personnel to the demands of industry, and the possibility of raising funds to allow this flexibility. The quality of the service is based on the expertise and presence of competent, well-trained staff.